Aptorum Group Limited(APM)Earnings, Financials & Key Ratios

APM•NASDAQ

$0.80

Price updated Jul 6, 2026

SectorHealthcare IndustryBiotechnology Sub-IndustryVaccines and Infectious Disease

AboutAptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; and ALS-1 to treat viral infections caused by influenza virus A. The company is also developing ALS-2/3 for the treatment of gram+ve bacterial infections; RPIDD, a pathogen molecular diagnostic; NativusWell DOI (NLS-2), a dietary supplement; NLS-1 for the treatment of endometriosis; DLS-1+2 to treat NSCLC with mutation; DLS-3, an autoimmune small molecule; and CLS-1 for the treatment of obesity. Its pipeline products enable the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platforms for treatment of metabolic diseases. The company also focuses on therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women's health, and other disease areas. In addition, it operates a medical clinic. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom.Show more

Revenue$0
EBITDA-$2M+48.7%
Net Income-$1M+68.1%
EPS (Diluted)-0.19+75.6%
ROE-10.68%+66.0%

APM Price & Volume

Aptorum Group Limited (APM) stock price & volume — 10-year historical chart

Loading chart...

Persistent Revenue Erosion Signals Critical Liquidity Distress

Investment Thesis • Updated 2024Q4

VerdictNegative: The company's total assets have declined to $16.1 million from a $44.2 million peak in 2020Q4

Growth:Contracting

Profitability:Negative

Financial:Vulnerable

Cash Flow:Burning

Primary Risk:Critical liquidity depletion

Key Thesis Takeaways

Aptorum Group faces a precarious outlook as its transition to a pre-revenue biotechnology model has resulted in the total evaporation of quarterly revenue compared to historical periods.
The company's reliance on external financing to sustain R&D, coupled with an accumulated deficit of $72.4 million, suggests a high risk of continued shareholder dilution.
Investors should monitor the company's ability to secure capital, as the current liquidity buffer is severely constrained by a current ratio of 0.22.

Verdict Logic

indicating a severe depletion of resources that threatens long-term operational viability.

APM Growth Metrics

Aptorum Group Limited (APM) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years-

5 Years-

3 Years-

TTM-84.8%

Profit CAGR

10 Years-

5 Years-

3 Years-

TTM79.65%

EPS CAGR

10 Years-

5 Years-

3 Years-

TTM82.83%

Return on Capital

10 Years-55.86%

5 Years-63.89%

3 Years-39.29%

Last Year-14.04%

Latest APM News

Recent stock market news and headlines for Aptorum Group Limited (APM)

GlobeNewsWire·Jun 22, 2026

Aptorum Group Announces Collaboration between DiamiR Biosciences and AlzLabs Precision Diagnostics for Alzheimer's Disease Biomarkers

NEW YORK, NY; NEW HAVEN, CT; and PRINCETON, NJ, June 22, 2026 (GLOBE NEWSWIRE) -- Aptorum Group Limited (NASDAQ: APM) ("Aptorum Group” or “Aptorum”), a clinical stage biopharmaceutical company dedicated to addressing unmet medical needs. and DiamiR Biosciences Corp. (“DiamiR”), a developer of innovative blood-based diagnostic tests for brain health and other diseases, today announced a collaboration between DiamiR and AlzLabs Precision Diagnostics (“AlzLabs”) to generate protein and microRNA blood-based biomarker data with the focus on Alzheimer's disease.

Newsfile Corp·Jun 18, 2026

Statement in Response to Silver Elephant's News Release Dated June 17, 2026

Toronto, Ontario--(Newsfile Corp. - June 18, 2026) - Andean Precious Metals Corp. (TSX: APM) (OTCQX: ANPMF) ("Andean" or the "Company") is aware of the news release issued by Silver Elephant Mining Corp. ("Silver Elephant") on June 17, 2026, regarding its filing of a Notice of Civil Claim in Vancouver, British Columbia. The allegations contained in Silver Elephant's news release and its Notice of Civil Claim are spurious and wholly without merit, and Andean strongly disagrees with Silver Elephant's characterization of the facts and circumstances described therein.

Peers Comparison

Key metrics vs top competitors for Aptorum Group Limited (APM)

Full Screener →

Company	Price	Market Cap	P/E Ratio	Rev Growth (1Y)	Net Margin	ROE	Div Yield
APMAptorum Group LimitedCurrent	$0.80	$5.09M	-4.22	—	—	-10.68%	—
CASICASI Pharmaceuticals, Inc.	$0.15	$2.33M	-0.06	-15.77%	-183.93%	—	—
ZLABZai Lab Limited	$19.08	$2.11B	-11.93	15.33%	-39.29%	-24.32%	—
NVAXNovavax, Inc.	$9.35	$1.54B	3.68	64.69%	-14.73%	—	—
AEYEAudioEye, Inc.	$7.24	$90.45M	-28.96	14.52%	-9.05%	-70.95%	—
AYTUAytu BioPharma, Inc.	$2.19	$17.74M	-1.01	1.84%	-60.17%	-148.91%	—

Compare APM vs Peers

Aptorum Group Limited (APM) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs CASI

Most directly comparable listed peer for APM.

Scale Benchmark

vs IQV

Larger-name benchmark to compare APM against a more recognizable public peer.

Peer Set

Compare Top 5

vs CASI, ZLAB, NVAX, AEYE

Get notified when APM posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

APM Frequently Asked Questions

Aptorum Group Limited (APM) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials

What is Aptorum Group Limited's revenue?

Aptorum Group Limited (APM) reported $0.4M in revenue for fiscal year 2025.

Is APM profitable?

Aptorum Group Limited (APM) reported a net loss of $7.1M for fiscal year 2025.

Dividend & Returns

What is APM's return on equity?

Aptorum Group Limited (APM) has a return on equity (ROE) of -10.7%. Negative ROE indicates the company is unprofitable.

What is Aptorum Group Limited's free cash flow?

Aptorum Group Limited (APM) had negative free cash flow of $9.0M in fiscal year 2025, likely due to heavy capital investments.

What if you invested $1,000 in APM back in 2017?

Total return calculator · dividends reinvested · 9+ years of data

See returns →

Company

Price

Market Cap

P/E Ratio

Rev Growth (1Y)

Net Margin

ROE

Div Yield

APMAptorum Group LimitedCurrent

$0.80

$5.09M

-4.22

—

-10.68%

—

CASICASI Pharmaceuticals, Inc.

$0.15

$2.33M

-0.06

-15.77%

-183.93%

—

ZLABZai Lab Limited

$19.08

$2.11B

-11.93

15.33%

-39.29%

-24.32%

—

NVAXNovavax, Inc.

$9.35

$1.54B

3.68

64.69%

-14.73%

—

AEYEAudioEye, Inc.

$7.24

$90.45M

-28.96

14.52%

-9.05%

-70.95%

—

AYTUAytu BioPharma, Inc.

$2.19

$17.74M

-1.01

1.84%

-60.17%

-148.91%

—